Strides Pharma Science share news and announcements
NSE: STARBSE: 532531Pharmaceuticals & BiotechnologySmall Cap
Formerly Strides Shasun
Last close ₹1,014.80up ₹16.40 (1.64%)BSE ₹1,012.15
Share price at the NSE close on 23 Oct 2026. Previous close ₹998.40.
52-week range of traded prices to 23 Oct 2026
₹768.65Low, 29 Jan 2026₹1,260.90High, 21 Sep 2026
- Next results date: the board meets on 29 Oct 2026 to consider: financial results.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹9,354 Cr580th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit.
- 15.2
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet.
- 3.0
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.49%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 21.7%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 15.1%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.53
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 3,12,38541.2% delivered
Strides Pharma Science share news and announcements
1,456 announcements, routine notices left out, newest first. Page 20 of 30.
Dec 2013
19 Dec · Business
Company has allotted 280,000 fully paid equity shares of Rs.10/- each on conversion of employee stock options under the Company's Employee Stock Option Schemes. Consequent to the above allotment, the paid-up equity share capital of the Company has increased from Rs. 592,856,210/- consisting of 59,285,621 equity shares of Rs. 10/- each to Rs. 595,656,210/- consisting of 59,565,621 equity shares of Rs. 10/- each.10 Dec · Change in Financial Year
Board of Directors of the Company have approved change of financial year of the Company from January-December to April-March effective April 01, 2014. In view of this, the current financial year will be for a period of 15 months i.e. January, 2013 to March, 2014.10 Dec · Corporate action
Company has fixed Record Date as December 20, 2013 for the purpose of determining the eligibility of shareholders for payment of special dividend.10 Dec · Dividend
Board of Directors of the Company at its meeting held on December 10, 2013 have approved a Special Dividend of Rs.500/- (Rupees Five Hundred Only) per equity share of Rs.10/- each to the shareholders of the Company.10 Dec · Dividend
Special dividend will be paid on or after December 27, 2013.9 Dec · Business
Company has allotted 123,000 fully paid equity shares of Rs.10/- each under the Strides Arcolab ESOP 2006 and ESOP 2008 Schemes. Consequent to the above allotment, the paid-up equity share capital of the Company has increased from Rs. 591,626,210/- consisting of 59,162,621 equity shares of Rs. 10/- each to Rs. 592,856,210/- consisting of 59,285,621 equity shares of Rs. 10/- each.5 Dec · Board meeting
To consider declaration of special dividend.
Nov 2013
6 Nov · Board meeting
To consider inter-alia, the unaudited financial results of the Company for the quarter ended September 30, 2013.
Oct 2013
17 Oct · Business
Company has allotted 1,250 fully paid equity shares of Rs.10/- each on conversion of employee stock options under Strides Arcolab ESOP 2008 Scheme. Consequent to the above allotment, the paid-up equity share capital of the Company has increased from Rs. 591,613,710/- consisting of 59,161,371 equity shares of Rs. 10/- each to Rs. 591,626,210/- consisting of 59,162,621 equity shares of Rs. 10/- each.
Sep 2013
27 Sep · Business
Company has allotted 51,250 fully paid equity shares of Rs.10/- each on conversion of employee stock options under Strides Arcolab ESOP 2008 Scheme. Consequent to the above allotment, the paid-up equity share capital of the Company has increased from Rs. 591,101,210/- consisting of 59,110,121 equity shares of Rs. 10/- each to Rs. 591,613,710/- consisting of 59,161,371 equity shares of Rs. 10/- each.
Aug 2013
28 Aug · Business
Company has allotted 10,000 fully paid equity shares of Rs.10/- each under Strides Arcolab ESOP 2008 (Director) Scheme to Non-Executive Directors of the Company. Consequent to the allotment, the paid-up equity share capital of the Company has increased from Rs. 591,001,210/- consisting of 59,100,121 equity shares of Rs. 10/- each to Rs. 591,101,210/- consisting of 59,110,121 equity shares of Rs. 10/- each.14 Aug · Updates
Strides Arcolab Limited had informed the Exchange earlier regarding shareholders' approval for increase in Fll limit upto 74%, the Company have been informed by Reserve Bank of India that they are reviewing the matter in consultation with Government of India. The Company has now informed the Exchange that the Reserve Bank of India on August 13, 2013 has directed all the Custodian Banks not to facilitate any purchase transactions on behalf of Flls for the Company till further intimation.8 Aug · Disclosure of Voting Pattern - Clause 35A
7 Aug · Legal
5 Aug · Meeting
Shareholders of the Company at their Extraordinary General Meeting held on August 03, 2013, have approved increase in the Fll Investment limit in the Company.FII's can now invest upto 74% of the paid up equity share capital of the Company under the Portfolio Investment Scheme. The current Fll holding in the Company is 52%.As required under the FEMA Regulation, the Company has made necessary intimation to the Reserve Bank of India confirming the shareholders' approval for the increased Fll investment limit.1 Aug · News Verification
News Verification : The media had reports that Strides Arcolab Limited has received Communication letter regarding concerns of the US FDA for one of its injectable units. The Exchange, in order to verify the accuracy or otherwise of the information reported in the media and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Strides Arcolab Limited has vide its letter inter-alia stated, "We confirm that as part of periodic US FDA inspection of one of our units in June 2013, the company received a 483, which is an observational document issued by the US FDA post inspection. The company has responded to the observations within the stipulated period and awaits response from US FDA."
Jul 2013
17 Jul · Board meeting
To consider inter-alia, the unaudited financial results of the Company for the quarter ended June 30, 2013.11 Jul · Business
Company has allotted 50,000 fully paid equity shares of Rs.10/- each on conversion of employee stock options under Strides Arcolab ESOP 2008 Scheme.Consequent to the above allotment, the paid-up equity share capital of the Company has increased from Rs. 590,501,210/- consisting of 59,050,121 equity shares of Rs. 10/- each to Rs. 591,001,210/- consisting of 59,100,121 equity shares of Rs. 10/- each.4 Jul · Updates
Board of Directors of the Company has approved the increase in the limit of investments by Foreign Institutional Investors (FIls) in the equity share capital of the Company from 49% to 74%, subject to approval of the Members, Reserve Bank of India and any other approvals as may be required.
Jun 2013
20 Jun · Business
Company has allotted 1800 fully paid equity shares of Rs. 10/- each on conversion of employee stock options under Strides Arcolab ESOP 2008 Scheme. Consequent to the above allotment, the paid-up equity share capital of the Company has increased from Rs. 590,483,210/- consisting of 59,048,321 equity shares of Rs. 10/- each to Rs. 590,501,210/- consisting of 59,050,121 equity shares of Rs. 10/- each.11 Jun · Disclosure of Voting Pattern - Clause 35A
5 Jun · Dividend
Strides Arcolab Limited had informed the Exchange on February 28, 2013 that the dividend payout date will be June 05, 2013, subject to the approval of dividend by the shareholders of the Company at the ensuing Annual General Meeting on May 31, 2013. The Company has now informed the Exchange that the dividend payout date for the financial year ended December 31, 2012 stands revised to June 17, 2013. Payment of dividend will be subject to the approval of the shareholders of the Company at the ensuing Annual General Meeting on June 10, 2013.
May 2013
17 May · Meeting
Register of Members and Transfer Books of the Company will remain closed from June 3, 2013 to June 10, 2013 ((both days inclusive) for the purpose of payment of dividend on equity shares for the year ended December 31, 2012, if declared and authorized at the ensuing AGM of the Company.
Apr 2013
18 Apr · Board meeting
To consider inter-alia, the unaudited financial results of the Company for the quarter ended March 31, 2013.